Connect with us


Lilly Plans To Cut Some Insulin Prices $44, Expand Cost Cap

Avatar for Kiara Grace




Eli Lilly will reduce the price of some older insulins later this year and provide more patients with immediate access to a cap on the costs they pay to fill prescriptions.

The actions announced on Wednesday provide critical relief to some people with diabetes who can face annual costs of thousands of dollars for the insulin they require to live. Lilly’s changes come as lawmakers and patient advocates pressure drugmakers to address rising prices.

Lilly said it would reduce list prices for Humalog, its most commonly prescribed insulin, and Humulin, another insulin, by 70% or more in the fourth quarter, which begins in October.

List prices are what a drugmaker initially establishes for a product and what people without insurance or with high deductible plans are sometimes forced to pay.

According to a Lilly spokesperson, the current list price for a 10-mL vial of the fast-acting, mealtime insulin Humalog is $274.70. This will be reduced to $66.40.

Similarly, she stated that the same amount of Humulin is currently listed at $148.70. That will now be $44.61.

According to Lilly CEO David Ricks, the company is making these changes to address issues that affect the price patients ultimately pay for its insulins.


Lilly Humulin is currently listed at $148.70. That will now be $44.61

He noted that discounts Lilly offers from its list prices often only reach patients through insurers or pharmacy benefit managers. High-deductible coverage can result in large bills at the pharmacy counter, especially at the beginning of the year when deductibles renew.

“We know the current healthcare system in the United States has gaps,” he said. “This makes a difficult disease like diabetes even more difficult to manage.”

Patient advocates have long advocated for insulin price reductions to assist uninsured individuals unaffected by price caps tied to insurance coverage.

Lilly’s planned price cuts “could provide some substantial price relief,” according to Stacie Dusetzina, a Vanderbilt University health policy professor who studies drug costs.

She noted that the changes are unlikely to have a significant financial impact on Lilly because the insulins are older, and some are already competitive.

Lilly also announced on Wednesday that the price of its authorized generic version of Humalog would be reduced to $25 per vial beginning in May.


Lilly will also launch biosimilar insulin in April to compete with Sanofi’s Lantus.

Ricks stated that because insurers and the pharmacy system will take time to implement the price cuts, the drugmaker will immediately cap monthly out-of-pocket costs for people not covered by Medicare’s prescription drug program at $35.

According to the drugmaker, the cap applies to people with commercial insurance and at most retail pharmacies.

People without insurance, according to Lilly, can find savings cards for the same amount of insulin on its website.

In January, the federal government began applying that cap to patients with Medicare coverage, which is available to people 65 and older and those with certain disabilities or illnesses.

Last month, President Joe Biden mentioned the cost cap in his annual State of the Union address. He proposed capping insulin costs at $35 for everyone.

Lilly responded to Biden’s call, according to a statement released on Wednesday.

“It’s a big deal, and other manufacturers should follow,” Biden said.

He also stated that Americans have faced “far too long” and much higher drug costs than people in other countries.

Aside from Eli Lilly and the French pharmaceutical company Sanofi, Novo Nordisk is another insulin manufacturer.

Sanofi and Novo Nordisk representatives said their companies offer a variety of programs that help people with and without insurance save money.

The pancreas produces insulin, which the body uses to convert food into energy. Diabetes patients do not produce enough insulin.

To survive, people with Type 1 diabetes must take insulin every day. According to the American Diabetes Association, more than 8 million Americans use insulin.

According to research, insulin prices have more than tripled in the last two decades. Pharmaceutical companies are under increasing pressure to assist patients.


Lilly is trying to get ahead of the issue and appear to the public as the good guy,

California has stated that it intends to investigate the possibility of producing cheaper insulin. Drugmakers also may face competition from companies like the nonprofit Civica, which plans to produce three insulins at a recommended price of at most $30 a vial, a spokeswoman said.

Drugmakers may see “the writing on the wall that high prices can’t last forever,” according to Larry Levitt, executive vice president of the Kaiser Family Foundation, a nonprofit that studies health care.

“Lilly is trying to get ahead of the issue and appear to the public as the good guy,” Levitt said, adding that nothing prevents Lilly from raising prices again.

According to Lilly officials, they have not raised the prices of any of their insulins since 2017.

Lilly CEO Ricks stated that Wednesday’s changes were made “because it’s time and the right thing to do.”

In 1923, two years after University of Toronto scientists discovered insulin, Indianapolis-based Eli Lilly and Company became the first company to commercialize it. The drugmaker then built its reputation on insulin production, even as it expanded into cancer treatments, antipsychotics, and other medications.

Last year, Lilly earned more than $3 billion in revenue from Humulin, Humalog, and it’s authorized generic. The previous year, they made more than $3.5 billion.

“These are treatments that have a long and successful history and should be less expensive for patients,” Dusetzina said.



Continue Reading


After Attacks, British Prime Minister Says American XL Bully Dogs Are Dangerous And Will Be Banned

Avatar for Kiara Grace




LONDON, England – Following a public uproar following recent attacks, British Prime Minister Rishi Sunak described American XL Bully dogs as a “danger to our communities” and announced measures to outlaw the breed.

Sunak stated that he had requested government ministers to convene a meeting of police and canine experts to officially identify the features of the American XL Bully, which is not recognized as a breed by organizations such as the Kennel Club in the United Kingdom or the American Kennel Club in the United States.

Sunak stated in a video message posted on X, formerly known as Twitter, “It is not currently a breed defined in law, so this vital first step must happen quickly.” “The breed will then be banned under the Dangerous Dogs Act, and new laws will be in place by the end of the year.”

The government has been pressed to act after an 11-year-old girl was attacked and critically injured by an American XL Bully in Birmingham, England, on Saturday. On Thursday, those fears were heightened after a man was killed in an incident that may have featured this sort of dog.


Following a public uproar following recent attacks, British Prime Minister Rishi Sunak described American XL Bully dogs as a “danger to our communities”.

Sunak stated, “The American XL Bully dog is a danger to our communities, particularly our children.” “I share the national outrage over the recent videos we’ve all seen.”

The pit bull terrier, Japanese tosa, dogo Argentino, and Fila Brasileiro are currently prohibited in the United Kingdom.

Some campaigners have requested that the American XL Bully, created from the American pit bull terrier, be added to the list because they believe the animals have deadly tendencies bred into them.

The Kennel Club of the United Kingdom does not recognize the XL Bully as a breed, arguing that no type of dog is intrinsically dangerous. According to the organization, breed-specific prohibitions do not address the most critical causes contributing to attacks, namely irresponsible dog owners who educate their dogs to be aggressive.

The bully breeds got their names from their use in blood sports, such as bull baiting. The dogs are more muscular than pit bulls and have a thicker bone structure.


Continue Reading


Johnson & Johnson Is Getting Rid Of Its Script Logo After More Than 130 Years

Avatar for Kiara Grace




Johnson & Johnson has approved a new logo.

The healthcare behemoth announced Thursday that it will replace its well-known distinctive script, which it has used since 1887, with a more modern design that reflects its increased emphasis on pharmaceuticals and medical devices.

The original script, based on co-founder James Wood Johnson’s signature, will be featured on consumer products such as infant shampoo from Kenvue, a new firm spun out from J&J.

J&J has focused on drugs and medical devices. The new appearance, which features a distinct shade of red, intends to reflect J&J’s transformation into a “pure play health care company,” according to executive vice president Vanessa Broadhurst.

J&J’s trademark logo was “one of the longest-used company emblems in the world,” according to a 2017 website post.

However, it began to show its age in an age of texting and emoticons.


Johnson & Johnson has approved a new logo.

According to marketing strategist Laura Ries, many youngsters no longer learn to write cursive in school. According to her, people may have recognized the signature but needed to be reading it. She claims that the new logo is easier to understand.

“Because it’s easier, it almost draws your attention to it,” Ries, who was not involved in the logo change, said.

Ries also discovered that customers were likelier to associate the script logo with Kenvue products on drugstore shelves, such as Band-Aids, Listerine, and Tylenol.


Johnson & Johnson has approved a new logo.

“Everyone washed their babies with Johnson & Johnson baby shampoo,” she explained.

According to a Kenvue spokeswoman, the J&J logo on products such as Band-Aids will be gradually erased.

The distinctive emblem was also found on bottles of the company’s now-discontinued talcum-based infant powder, which sparked cancer lawsuits. J&J has stated that the powder was completely safe.

J&J’s consumer business helped the company become the world’s largest manufacturer of healthcare items, with annual revenues exceeding $90 billion. However, by the time the split was announced in late 2021, its pharmaceutical and medical device divisions had comfortably overtaken it in size.

J&J, based in New Brunswick, New Jersey, J&J will also rebrand its Janssen pharmaceutical division to J&J Innovative Medicine. Its medical device and technology division will be known as MedTech.


Continue Reading

U.K News

1 Chip Challenge: Amazon And EBay Pull Spicy Tortilla From UK Shop

Avatar for Kiara Grace




Amazon and eBay have pulled from sale a super-hot tortilla chip linked to the death of an American adolescent.

Harris Wolobah’s parents feel the One Chip Challenge was to blame for his death last week.

It was removed from shelves in the United States, where it was widely distributed, but imports from global vendors remained available.

After being contacted by BBC Newsbeat, Amazon stated it would remove the goods from its sites in the United States, the United Kingdom, Europe, the Middle East, and Africa.

The online store also intends to notify any international buyers who have lately purchased the snack.

An eBay spokeswoman stated that user safety was a “top priority” and that sale listings had been removed.

“We are closely monitoring our site and will remove any additional listings that appear,” they added.

Harris’s death has not been officially determined, but his parents have urged for the One Chip Challenge to be stopped.

Paqui, a snack company, claims that the single tortilla, which comes in a coffin-shaped box, has a blend of “the hottest peppers available.”

Millions of people have watched YouTubers and TikTokers take the viral challenge and respond violently.

The challenge’s popularity is claimed to have prompted many youngsters to purchase the product, which comes with a warning label, to attempt it for themselves.


Amazon and eBay have pulled from sale a super-hot tortilla chip linked to the death of an American adolescent.

Paqui issued a statement on its website on Thursday announcing its decision to withdraw merchandise from American retailers.

According to the firm, the challenge is “intended for adults only” and is inappropriate for anyone with underlying health concerns or allergies.

However, it reported an “increase in teens and other individuals failing to heed these warnings.”

“As a result, while the product continues to meet food safety standards, we are actively working with our retailers to remove the product from shelves,” the company said.


A Paqui representative told Newsbeat, “We are deeply saddened by the death of Harris Wolobah and express our condolences to the family.”

“We care about all of our customers and have decided to remove the product from the shelves.”

They claimed that the product’s label “clearly states” that it is unsuitable for youngsters or those sensitive to spicy foods.

“We are actively working with our retailers and are offering refunds for any purchases of our single-serve one chip challenge product,” the company said.

The Food Standards Agency (FSA) in the United Kingdom told Newsbeat that it is working to determine where the product is distributed.

The FSA’s Tina Potter stated, “So far, we have not received any reports of illness here.”

In most cases, eating chillis and spicy foods is regarded as harmless, depending on your tolerance.

However, the body’s reaction to extremely spicy foods might resemble its response to burns, resulting in symptoms such as perspiration.


Continue Reading

Recent News